Scott Sagel
Concepts (412)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 107 | 2026 | 1118 | 13.500 |
Why?
| | Aminophenols | 25 | 2026 | 188 | 5.150 |
Why?
| | Quinolones | 25 | 2026 | 185 | 4.460 |
Why?
| | Kartagener Syndrome | 25 | 2026 | 31 | 3.660 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 31 | 2026 | 358 | 3.600 |
Why?
| | Ciliary Motility Disorders | 16 | 2025 | 24 | 3.330 |
Why?
| | Benzodioxoles | 15 | 2026 | 145 | 3.160 |
Why?
| | Sputum | 27 | 2026 | 314 | 2.980 |
Why?
| | Chloride Channel Agonists | 16 | 2026 | 95 | 2.380 |
Why?
| | Inflammation | 17 | 2026 | 2900 | 1.980 |
Why?
| | Pyrazoles | 9 | 2026 | 499 | 1.820 |
Why?
| | Lung | 26 | 2025 | 4159 | 1.690 |
Why?
| | Pyrrolidines | 7 | 2026 | 114 | 1.690 |
Why?
| | Indoles | 9 | 2026 | 482 | 1.690 |
Why?
| | Pyridines | 8 | 2026 | 614 | 1.590 |
Why?
| | Anti-Bacterial Agents | 16 | 2025 | 1902 | 1.550 |
Why?
| | Respiratory Function Tests | 21 | 2024 | 570 | 1.520 |
Why?
| | Respiratory System Agents | 3 | 2022 | 23 | 1.440 |
Why?
| | Bronchiectasis | 4 | 2025 | 112 | 1.400 |
Why?
| | Biomarkers | 26 | 2026 | 4258 | 1.390 |
Why?
| | Pseudomonas Infections | 11 | 2025 | 218 | 1.310 |
Why?
| | Azithromycin | 7 | 2025 | 104 | 1.300 |
Why?
| | Genetic Testing | 7 | 2021 | 478 | 1.280 |
Why?
| | Aminopyridines | 6 | 2022 | 126 | 1.270 |
Why?
| | Neonatal Screening | 5 | 2021 | 175 | 1.270 |
Why?
| | Cilia | 17 | 2025 | 173 | 1.270 |
Why?
| | Child | 81 | 2026 | 22493 | 1.200 |
Why?
| | Lung Diseases | 6 | 2023 | 795 | 1.190 |
Why?
| | Mycobacterium avium-intracellulare Infection | 3 | 2021 | 64 | 1.190 |
Why?
| | Meconium Ileus | 2 | 2026 | 12 | 1.160 |
Why?
| | Adolescent | 75 | 2026 | 22282 | 1.130 |
Why?
| | Forced Expiratory Volume | 17 | 2025 | 493 | 1.050 |
Why?
| | Drug Combinations | 12 | 2026 | 378 | 1.020 |
Why?
| | Anti-Inflammatory Agents | 4 | 2020 | 483 | 1.020 |
Why?
| | Mutation | 29 | 2022 | 4120 | 0.980 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 648 | 0.970 |
Why?
| | Trypsinogen | 3 | 2021 | 11 | 0.970 |
Why?
| | Deoxyribonuclease I | 1 | 2025 | 38 | 0.940 |
Why?
| | Saline Solution, Hypertonic | 1 | 2025 | 42 | 0.930 |
Why?
| | Female | 99 | 2026 | 77795 | 0.850 |
Why?
| | Humans | 141 | 2026 | 144228 | 0.840 |
Why?
| | Young Adult | 45 | 2026 | 13949 | 0.840 |
Why?
| | Disease Progression | 19 | 2025 | 2874 | 0.840 |
Why?
| | Male | 95 | 2026 | 71757 | 0.820 |
Why?
| | Vitamins | 2 | 2018 | 177 | 0.810 |
Why?
| | Prospective Studies | 31 | 2026 | 7911 | 0.750 |
Why?
| | Leukocyte Elastase | 8 | 2026 | 76 | 0.740 |
Why?
| | Antioxidants | 3 | 2018 | 581 | 0.730 |
Why?
| | Pseudomonas aeruginosa | 11 | 2023 | 350 | 0.720 |
Why?
| | Ethambutol | 1 | 2021 | 27 | 0.680 |
Why?
| | Breath Tests | 6 | 2026 | 81 | 0.680 |
Why?
| | Algorithms | 4 | 2021 | 1844 | 0.670 |
Why?
| | Rifampin | 1 | 2021 | 81 | 0.660 |
Why?
| | Child, Preschool | 35 | 2026 | 11656 | 0.640 |
Why?
| | Nitric Oxide | 6 | 2026 | 903 | 0.590 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 89 | 0.590 |
Why?
| | Longitudinal Studies | 15 | 2026 | 2955 | 0.580 |
Why?
| | Quinolines | 5 | 2026 | 185 | 0.580 |
Why?
| | Dyneins | 7 | 2024 | 35 | 0.560 |
Why?
| | Dietary Supplements | 3 | 2018 | 577 | 0.520 |
Why?
| | Malnutrition | 1 | 2018 | 84 | 0.520 |
Why?
| | C-Reactive Protein | 8 | 2022 | 419 | 0.520 |
Why?
| | Nontuberculous Mycobacteria | 3 | 2023 | 208 | 0.500 |
Why?
| | Hospitalization | 3 | 2025 | 2346 | 0.480 |
Why?
| | Adult | 46 | 2026 | 40230 | 0.470 |
Why?
| | United States | 22 | 2025 | 15641 | 0.460 |
Why?
| | Drug Discovery | 1 | 2016 | 155 | 0.460 |
Why?
| | Infant | 24 | 2026 | 9911 | 0.460 |
Why?
| | Leukocyte L1 Antigen Complex | 5 | 2022 | 38 | 0.450 |
Why?
| | Infant, Newborn | 17 | 2026 | 6380 | 0.450 |
Why?
| | Specimen Handling | 3 | 2025 | 185 | 0.440 |
Why?
| | Mycobacterium Infections, Nontuberculous | 4 | 2023 | 366 | 0.430 |
Why?
| | Sweat | 5 | 2025 | 48 | 0.420 |
Why?
| | Metabolomics | 1 | 2019 | 731 | 0.410 |
Why?
| | Automation | 1 | 2014 | 104 | 0.410 |
Why?
| | Retrospective Studies | 21 | 2025 | 16805 | 0.400 |
Why?
| | Granulocyte Colony-Stimulating Factor | 4 | 2022 | 89 | 0.400 |
Why?
| | Exocrine Pancreatic Insufficiency | 2 | 2010 | 23 | 0.390 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 395 | 0.380 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2014 | 131 | 0.380 |
Why?
| | Clinical Trials as Topic | 5 | 2015 | 1048 | 0.370 |
Why?
| | Treatment Outcome | 16 | 2026 | 11501 | 0.370 |
Why?
| | Blood Glucose | 5 | 2025 | 2325 | 0.360 |
Why?
| | Respiratory System | 4 | 2019 | 159 | 0.360 |
Why?
| | Microbiota | 5 | 2023 | 782 | 0.360 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2011 | 16 | 0.350 |
Why?
| | Tomography, X-Ray Computed | 7 | 2025 | 2788 | 0.350 |
Why?
| | Staphylococcal Infections | 3 | 2019 | 390 | 0.330 |
Why?
| | Sensitivity and Specificity | 7 | 2021 | 1986 | 0.330 |
Why?
| | Vitamin K Deficiency | 1 | 2010 | 9 | 0.330 |
Why?
| | Cohort Studies | 14 | 2025 | 5876 | 0.330 |
Why?
| | Vitamin A Deficiency | 1 | 2010 | 24 | 0.330 |
Why?
| | Cytokines | 6 | 2023 | 2098 | 0.320 |
Why?
| | Severity of Illness Index | 10 | 2024 | 2930 | 0.310 |
Why?
| | Otitis Media with Effusion | 2 | 2025 | 20 | 0.310 |
Why?
| | Bronchoscopy | 2 | 2008 | 227 | 0.310 |
Why?
| | Quality of Life | 5 | 2024 | 3146 | 0.310 |
Why?
| | Secretory Leukocyte Peptidase Inhibitor | 1 | 2009 | 6 | 0.300 |
Why?
| | Lactoferrin | 1 | 2009 | 36 | 0.300 |
Why?
| | Bronchitis | 1 | 2009 | 36 | 0.290 |
Why?
| | Muramidase | 1 | 2009 | 67 | 0.290 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 187 | 0.280 |
Why?
| | Proteomics | 3 | 2022 | 1194 | 0.280 |
Why?
| | Tomography | 2 | 2018 | 45 | 0.270 |
Why?
| | Diverticulum | 1 | 2007 | 15 | 0.270 |
Why?
| | Tracheal Diseases | 1 | 2007 | 15 | 0.270 |
Why?
| | Tracheoesophageal Fistula | 1 | 2007 | 37 | 0.260 |
Why?
| | Administration, Oral | 3 | 2018 | 842 | 0.260 |
Why?
| | Cough | 2 | 2025 | 134 | 0.250 |
Why?
| | Genotype | 10 | 2025 | 1839 | 0.250 |
Why?
| | Data Interpretation, Statistical | 2 | 2021 | 371 | 0.250 |
Why?
| | Digestive System Surgical Procedures | 1 | 2007 | 103 | 0.250 |
Why?
| | Heterotaxy Syndrome | 2 | 2023 | 14 | 0.240 |
Why?
| | Reproductive Health | 2 | 2017 | 92 | 0.240 |
Why?
| | Phenotype | 8 | 2025 | 3185 | 0.240 |
Why?
| | Respiratory Distress Syndrome, Newborn | 2 | 2025 | 106 | 0.240 |
Why?
| | Cyclopropanes | 1 | 2026 | 82 | 0.240 |
Why?
| | Proteins | 4 | 2024 | 1029 | 0.230 |
Why?
| | Pulmonary Atelectasis | 1 | 2025 | 16 | 0.230 |
Why?
| | Leukocyte Count | 5 | 2012 | 318 | 0.230 |
Why?
| | Bacteria | 5 | 2023 | 892 | 0.220 |
Why?
| | Middle Ear Ventilation | 1 | 2025 | 18 | 0.220 |
Why?
| | Hearing Loss, Conductive | 1 | 2025 | 24 | 0.220 |
Why?
| | Interleukin-8 | 7 | 2012 | 273 | 0.220 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2005 | 133 | 0.210 |
Why?
| | Age Factors | 5 | 2020 | 3295 | 0.210 |
Why?
| | Chlorides | 3 | 2022 | 136 | 0.210 |
Why?
| | Probability | 3 | 2016 | 306 | 0.210 |
Why?
| | Glucose Tolerance Test | 5 | 2025 | 376 | 0.210 |
Why?
| | Situs Inversus | 1 | 2023 | 3 | 0.210 |
Why?
| | DNA, Bacterial | 4 | 2017 | 341 | 0.210 |
Why?
| | Case-Control Studies | 8 | 2026 | 3618 | 0.210 |
Why?
| | Rhinitis | 2 | 2019 | 173 | 0.210 |
Why?
| | Oropharynx | 3 | 2015 | 47 | 0.200 |
Why?
| | Cytoskeletal Proteins | 4 | 2024 | 156 | 0.200 |
Why?
| | Models, Neurological | 1 | 2006 | 255 | 0.200 |
Why?
| | Axonemal Dyneins | 4 | 2025 | 9 | 0.200 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1088 | 0.200 |
Why?
| | Sinusitis | 2 | 2019 | 237 | 0.200 |
Why?
| | Mucociliary Clearance | 2 | 2021 | 45 | 0.200 |
Why?
| | Follow-Up Studies | 7 | 2018 | 5327 | 0.190 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 310 | 0.190 |
Why?
| | Metagenome | 3 | 2013 | 148 | 0.190 |
Why?
| | Fetal Diseases | 1 | 2024 | 191 | 0.190 |
Why?
| | Respiration | 2 | 2026 | 209 | 0.190 |
Why?
| | Monitoring, Immunologic | 1 | 2002 | 23 | 0.190 |
Why?
| | Respiration Disorders | 1 | 2023 | 78 | 0.190 |
Why?
| | Genetic Markers | 4 | 2016 | 338 | 0.190 |
Why?
| | Calreticulin | 1 | 2022 | 22 | 0.180 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1357 | 0.180 |
Why?
| | Uteroglobin | 1 | 2022 | 32 | 0.180 |
Why?
| | HMGB Proteins | 1 | 2022 | 14 | 0.180 |
Why?
| | Chemistry, Clinical | 1 | 2002 | 6 | 0.180 |
Why?
| | Serum Amyloid A Protein | 2 | 2019 | 33 | 0.180 |
Why?
| | Peptide Hydrolases | 1 | 2023 | 106 | 0.180 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.180 |
Why?
| | Hydrogen | 1 | 2022 | 73 | 0.180 |
Why?
| | Bone Density | 1 | 2026 | 501 | 0.180 |
Why?
| | Synapses | 1 | 2006 | 436 | 0.180 |
Why?
| | Antibiotics, Antitubercular | 1 | 2021 | 35 | 0.170 |
Why?
| | Prognosis | 5 | 2018 | 4221 | 0.170 |
Why?
| | Body Mass Index | 5 | 2020 | 2446 | 0.170 |
Why?
| | Desmosine | 2 | 2012 | 6 | 0.170 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5776 | 0.160 |
Why?
| | DNA Mutational Analysis | 5 | 2014 | 408 | 0.160 |
Why?
| | Rhodospirillaceae | 1 | 2020 | 4 | 0.160 |
Why?
| | Disease Management | 3 | 2015 | 639 | 0.160 |
Why?
| | Leptin | 1 | 2022 | 244 | 0.160 |
Why?
| | Cross-Over Studies | 2 | 2021 | 596 | 0.160 |
Why?
| | Pregnancy | 5 | 2026 | 7180 | 0.160 |
Why?
| | Glucose | 2 | 2023 | 1044 | 0.160 |
Why?
| | Mycobacterium abscessus | 1 | 2021 | 119 | 0.160 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 321 | 0.150 |
Why?
| | Patient Acuity | 1 | 2019 | 47 | 0.150 |
Why?
| | Sleep Apnea, Central | 1 | 1999 | 13 | 0.150 |
Why?
| | Autonomic Nervous System Diseases | 1 | 1999 | 32 | 0.150 |
Why?
| | Alleles | 4 | 2017 | 883 | 0.150 |
Why?
| | Proteome | 2 | 2022 | 511 | 0.150 |
Why?
| | Antitubercular Agents | 1 | 2021 | 215 | 0.150 |
Why?
| | Pneumonia | 2 | 2017 | 641 | 0.140 |
Why?
| | Respiratory Tract Diseases | 1 | 2020 | 181 | 0.140 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2097 | 0.140 |
Why?
| | Prevalence | 3 | 2025 | 2820 | 0.140 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 788 | 0.140 |
Why?
| | Nutritional Status | 2 | 2018 | 351 | 0.140 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2018 | 21 | 0.140 |
Why?
| | Air | 1 | 2018 | 45 | 0.140 |
Why?
| | Hypoglycemia | 1 | 2023 | 473 | 0.140 |
Why?
| | Machine Learning | 1 | 2024 | 578 | 0.140 |
Why?
| | Oxidative Stress | 2 | 2018 | 1376 | 0.140 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 85 | 0.140 |
Why?
| | Saliva | 2 | 2015 | 249 | 0.130 |
Why?
| | Hirschsprung Disease | 1 | 1999 | 89 | 0.130 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2023 | 1223 | 0.130 |
Why?
| | Reproductive Health Services | 1 | 2017 | 18 | 0.130 |
Why?
| | Health Services Misuse | 1 | 2017 | 34 | 0.130 |
Why?
| | Double-Blind Method | 3 | 2018 | 2023 | 0.130 |
Why?
| | Tobramycin | 2 | 2023 | 54 | 0.130 |
Why?
| | Clofazimine | 1 | 2017 | 15 | 0.130 |
Why?
| | Neutrophils | 3 | 2015 | 1146 | 0.130 |
Why?
| | Insulin | 2 | 2025 | 2506 | 0.130 |
Why?
| | Lipids | 1 | 2022 | 701 | 0.130 |
Why?
| | Coinfection | 2 | 2020 | 140 | 0.130 |
Why?
| | Axoneme | 2 | 2013 | 10 | 0.120 |
Why?
| | Body Height | 1 | 2017 | 202 | 0.120 |
Why?
| | Neurons | 1 | 2006 | 1639 | 0.120 |
Why?
| | Immunologic Tests | 1 | 2016 | 15 | 0.120 |
Why?
| | Middle Aged | 16 | 2025 | 35731 | 0.120 |
Why?
| | Sexual Health | 1 | 2017 | 67 | 0.120 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 246 | 0.120 |
Why?
| | Body Weight | 1 | 2020 | 993 | 0.120 |
Why?
| | Spirometry | 4 | 2015 | 264 | 0.110 |
Why?
| | Diagnostic Tests, Routine | 1 | 2016 | 110 | 0.110 |
Why?
| | Exome | 5 | 2014 | 239 | 0.110 |
Why?
| | Targeted Gene Repair | 1 | 2015 | 1 | 0.110 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 125 | 0.110 |
Why?
| | Time Factors | 4 | 2018 | 7081 | 0.110 |
Why?
| | Patient Selection | 1 | 2019 | 696 | 0.110 |
Why?
| | Microtubule-Associated Proteins | 2 | 2013 | 197 | 0.110 |
Why?
| | Pedigree | 5 | 2013 | 513 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 441 | 0.110 |
Why?
| | Postoperative Complications | 1 | 2007 | 2904 | 0.110 |
Why?
| | Zebrafish | 3 | 2013 | 526 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1826 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2023 | 1255 | 0.110 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 25 | 0.110 |
Why?
| | Nasal Mucosa | 4 | 2019 | 111 | 0.100 |
Why?
| | Hyperglycemia | 1 | 2018 | 370 | 0.100 |
Why?
| | Microscopy, Electron, Transmission | 4 | 2016 | 157 | 0.100 |
Why?
| | Homozygote | 3 | 2020 | 201 | 0.100 |
Why?
| | Antigens, Surface | 1 | 2013 | 157 | 0.100 |
Why?
| | Ubiquinone | 2 | 2010 | 35 | 0.100 |
Why?
| | Survival Rate | 2 | 2018 | 2036 | 0.100 |
Why?
| | Intestine, Small | 1 | 2014 | 166 | 0.100 |
Why?
| | Sexual Behavior | 1 | 2017 | 490 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 330 | 0.100 |
Why?
| | Vital Capacity | 1 | 2014 | 311 | 0.100 |
Why?
| | GTP-Binding Proteins | 1 | 2013 | 154 | 0.100 |
Why?
| | Linear Models | 3 | 2024 | 859 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 85 | 0.090 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 62 | 0.090 |
Why?
| | DNA | 2 | 2018 | 1430 | 0.090 |
Why?
| | Elastin | 1 | 2012 | 84 | 0.090 |
Why?
| | Precision Medicine | 1 | 2016 | 457 | 0.090 |
Why?
| | Proteolysis | 1 | 2012 | 177 | 0.090 |
Why?
| | Glycoproteins | 1 | 2013 | 357 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 115 | 0.090 |
Why?
| | Models, Statistical | 1 | 2016 | 680 | 0.090 |
Why?
| | Turbinates | 1 | 2011 | 14 | 0.080 |
Why?
| | Feasibility Studies | 2 | 2025 | 1072 | 0.080 |
Why?
| | Nasal Cavity | 1 | 2011 | 63 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 324 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1058 | 0.080 |
Why?
| | Biomarkers, Pharmacological | 1 | 2010 | 26 | 0.080 |
Why?
| | Dinoprost | 1 | 2010 | 50 | 0.080 |
Why?
| | Inflammation Mediators | 2 | 2005 | 511 | 0.080 |
Why?
| | Biopsy | 4 | 2015 | 1069 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 1 | 2013 | 580 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1531 | 0.080 |
Why?
| | Metagenomics | 2 | 2021 | 180 | 0.080 |
Why?
| | Interprofessional Relations | 1 | 2012 | 282 | 0.080 |
Why?
| | Microbial Sensitivity Tests | 2 | 2021 | 372 | 0.080 |
Why?
| | Morbidity | 2 | 2018 | 322 | 0.070 |
Why?
| | Membrane Potentials | 2 | 2010 | 280 | 0.070 |
Why?
| | Chronic Disease | 2 | 2015 | 1826 | 0.070 |
Why?
| | Canada | 2 | 2024 | 425 | 0.070 |
Why?
| | Pseudomonas | 2 | 2022 | 31 | 0.070 |
Why?
| | Lung Injury | 1 | 2012 | 227 | 0.070 |
Why?
| | Exotoxins | 1 | 2008 | 16 | 0.070 |
Why?
| | Confidence Intervals | 1 | 2009 | 331 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2590 | 0.070 |
Why?
| | Administration, Inhalation | 2 | 2023 | 592 | 0.070 |
Why?
| | Heterozygote | 1 | 2009 | 315 | 0.070 |
Why?
| | ROC Curve | 2 | 2026 | 608 | 0.070 |
Why?
| | Electric Impedance | 2 | 2018 | 113 | 0.070 |
Why?
| | Peroxidase | 2 | 2022 | 170 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 711 | 0.070 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 39 | 0.070 |
Why?
| | RNA Precursors | 1 | 2008 | 157 | 0.060 |
Why?
| | Pregnancy Rate | 2 | 2017 | 70 | 0.060 |
Why?
| | Asthma | 3 | 2026 | 1916 | 0.060 |
Why?
| | Sequence Analysis, DNA | 3 | 2015 | 828 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2014 | 1493 | 0.060 |
Why?
| | Diagnostic Errors | 1 | 2007 | 176 | 0.060 |
Why?
| | Genomics | 2 | 2021 | 836 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2413 | 0.060 |
Why?
| | Biomedical Research | 1 | 2012 | 714 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2010 | 3402 | 0.060 |
Why?
| | Tidal Volume | 1 | 2026 | 112 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 28 | 0.060 |
Why?
| | Tympanic Membrane Perforation | 1 | 2025 | 17 | 0.060 |
Why?
| | Audiometry, Pure-Tone | 1 | 2025 | 34 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2013 | 2859 | 0.060 |
Why?
| | Incidence | 2 | 2025 | 2852 | 0.060 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2026 | 277 | 0.050 |
Why?
| | Needs Assessment | 2 | 2017 | 400 | 0.050 |
Why?
| | Cephalosporins | 1 | 2024 | 47 | 0.050 |
Why?
| | Colorado | 2 | 2018 | 4591 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 108 | 0.050 |
Why?
| | Reference Values | 2 | 2017 | 807 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2008 | 452 | 0.050 |
Why?
| | Vasodilator Agents | 1 | 2006 | 332 | 0.050 |
Why?
| | Exercise Tolerance | 1 | 2006 | 288 | 0.050 |
Why?
| | Microscopy, Electron | 2 | 2015 | 415 | 0.050 |
Why?
| | Monitoring, Physiologic | 1 | 2025 | 291 | 0.050 |
Why?
| | Diabetic Retinopathy | 1 | 2006 | 206 | 0.050 |
Why?
| | Piperazines | 1 | 2006 | 394 | 0.050 |
Why?
| | Symptom Assessment | 1 | 2024 | 130 | 0.050 |
Why?
| | Registries | 2 | 2025 | 2248 | 0.050 |
Why?
| | Pancreatic Elastase | 1 | 2022 | 55 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2009 | 854 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2024 | 530 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10641 | 0.050 |
Why?
| | Glucagon | 1 | 2023 | 106 | 0.050 |
Why?
| | Cell Count | 1 | 2002 | 324 | 0.050 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 25 | 0.040 |
Why?
| | Constipation | 1 | 2022 | 96 | 0.040 |
Why?
| | Nucleotides | 1 | 2022 | 126 | 0.040 |
Why?
| | Computer Simulation | 1 | 2006 | 1033 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2020 | 37 | 0.040 |
Why?
| | Mutant Proteins | 1 | 2020 | 105 | 0.040 |
Why?
| | Down Syndrome | 1 | 2007 | 524 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2021 | 127 | 0.040 |
Why?
| | Recovery of Function | 1 | 2024 | 700 | 0.040 |
Why?
| | Prediabetic State | 1 | 2023 | 257 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2017 | 1407 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 23 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1999 | 306 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 992 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 696 | 0.030 |
Why?
| | Pilot Projects | 2 | 2017 | 1858 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 62 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2023 | 706 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 1999 | 292 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 396 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1314 | 0.030 |
Why?
| | Ontario | 1 | 2016 | 94 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 176 | 0.030 |
Why?
| | Microscopy, Video | 1 | 2015 | 25 | 0.030 |
Why?
| | Respiratory Therapy | 1 | 2015 | 25 | 0.030 |
Why?
| | Radiography | 1 | 2017 | 838 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 1003 | 0.030 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2015 | 39 | 0.030 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 43 | 0.030 |
Why?
| | Staphylococcus | 1 | 2015 | 74 | 0.030 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 40 | 0.030 |
Why?
| | North America | 1 | 2015 | 309 | 0.030 |
Why?
| | Pneumococcal Vaccines | 1 | 2015 | 129 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2017 | 6031 | 0.030 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1984 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 70 | 0.030 |
Why?
| | Counseling | 1 | 2017 | 400 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2081 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1509 | 0.030 |
Why?
| | Planarians | 1 | 2013 | 1 | 0.030 |
Why?
| | Genetic Therapy | 1 | 2016 | 323 | 0.030 |
Why?
| | Chlamydomonas | 1 | 2013 | 3 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 865 | 0.030 |
Why?
| | Xenopus laevis | 1 | 2013 | 103 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2013 | 133 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2014 | 564 | 0.020 |
Why?
| | Cytoplasm | 1 | 2013 | 270 | 0.020 |
Why?
| | Genes, Recessive | 1 | 2012 | 78 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2032 | 0.020 |
Why?
| | Computer Communication Networks | 1 | 2012 | 32 | 0.020 |
Why?
| | Placebos | 1 | 2012 | 192 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 346 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 207 | 0.020 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2012 | 140 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 375 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 376 | 0.020 |
Why?
| | Airway Remodeling | 1 | 2012 | 71 | 0.020 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 27 | 0.020 |
Why?
| | Biota | 1 | 2011 | 35 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2012 | 403 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2096 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2013 | 858 | 0.020 |
Why?
| | Influenza Vaccines | 1 | 2015 | 527 | 0.020 |
Why?
| | Autoantigens | 1 | 2013 | 432 | 0.020 |
Why?
| | Biofilms | 1 | 2013 | 279 | 0.020 |
Why?
| | Ion Channels | 1 | 2010 | 130 | 0.020 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2013 | 559 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2013 | 636 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 618 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2012 | 791 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 42 | 0.020 |
Why?
| | gamma-Tocopherol | 1 | 2007 | 7 | 0.020 |
Why?
| | beta Carotene | 1 | 2007 | 20 | 0.020 |
Why?
| | Mexico | 1 | 2008 | 232 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 166 | 0.020 |
Why?
| | Micelles | 1 | 2007 | 40 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2013 | 1128 | 0.020 |
Why?
| | Biological Availability | 1 | 2007 | 141 | 0.020 |
Why?
| | Protein Binding | 1 | 2013 | 2269 | 0.020 |
Why?
| | Leukocytes | 1 | 2008 | 297 | 0.020 |
Why?
| | Animals | 3 | 2013 | 38231 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 766 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1122 | 0.010 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 60 | 0.010 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1075 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 999 | 0.010 |
Why?
| | Sulfones | 1 | 2006 | 127 | 0.010 |
Why?
| | Aged | 2 | 2017 | 25675 | 0.010 |
Why?
| | Genetic Carrier Screening | 1 | 2004 | 32 | 0.010 |
Why?
| | Purines | 1 | 2006 | 188 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 8154 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5626 | 0.010 |
Why?
| | Infant Care | 1 | 2004 | 44 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2630 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2914 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2004 | 149 | 0.010 |
Why?
|
|
Sagel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|